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Abstract: Genistein, a soy-derived isoflavone, may improve cardiovascular risk profile in postmenopausal
women with metabolic syndrome (MetS), but few literature data on its cardiac effects in humans
are available. The aim of this sub-study of a randomized double-blind case-control study
was to analyze the effect on cardiac function of one-year genistein dietary supplementation in
22 post-menopausal patients with MetS. Participants received 54 mg/day of genistein (n = 11) or
placebo (n = 11) in combination with a Mediterranean-style diet and regular exercise. Left ventricular
(LV) systolic function was assessed as the primary endpoint, according to conventional and
strain-echocardiography measurements. Also, left atrial (LA) morphofunctional indices were
investigated at baseline and at the final visit. Results were expressed as median with interquartile
range (IQ). A significant improvement of LV ejection fraction (20.3 (IQ 12.5) vs. −1.67 (IQ 24.8);
p = 0.040)), and LA area fractional change (11.1 (IQ 22.6) vs. 2.8 (9.5); p = 0.034)) were observed in
genistein patients compared to the controls, following 12 months of treatment. In addition, body
surface area indexed LA systolic volume and peak LA longitudinal strain significantly changed
from basal to the end of the study in genistein-treated patients. One-year supplementation with
54 mg/day of pure genistein improved both LV ejection fraction and LA remodeling and function in
postmenopausal women with MetS.
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1. Introduction
Estrogen favorably influences calcium homeostasis, serum lipid levels, blood pressure control,
inflammatory status, and vascular reactivity in women [1–5]. Data from Italian and other European
registries indicate that postmenopausal women presenting with traits of metabolic syndrome (MetS),
mostly diabetes mellitus (DM) and hyperlipemia, are at high risk of cardiovascular (CV) events [1,6,7].
Moreover, the use of lipid-lowering therapy is strongly influenced by reimbursement criteria
revision, and the female gender was identified as a patient-related predictor of low adherence [8–10].
The advantages of estrogen supplementation are preserved in early menopause, failing to maintain
cardiovascular protection, thus further therapeutic options continue to be studied [11–13]. Genistein
aglycone (hereinafter referred to as genistein) is a soy isoflavone, which has progressively gained
clinical consideration for the management of postmenopausal symptoms. Its molecular structure
resembles that of 17β–estradiol and binds the same estrogen-receptors in a dose-dependent manner.
Regular supplementation in combination with a Mediterranean-style diet, regular exercise, and medical
therapy improve CV risk, endothelial function, and vascular reactivity in MetS women, although,
to date, very little data are available concerning the effect of genistein on heart function [12,14–18].
The aim of this study was therefore to investigate whether genistein therapy might influence
heart function in postmenopausal patients with MetS.
2. Materials and Methods
2.1. Design and Setting
A group of postmenopausal women, affected by type-2 DM and free from previous CV events,
was enrolled from the population of postmenopausal women referred to the Department of Clinical and
Experimental Medicine (University Hospital, Messina, Italy) for MetS. All patients were of Caucasian
origin. This study was planned as a sub-study aimed to investigate the influence of genistein on
heart function, from the original randomized multicenter clinical trial (clinicaltrials.gov registration
NCT00541710) managed in collaboration with the University of Palermo (Palermo, Italy) and the
University of Magna Graecia (Catanzaro, Italy) [16]. All patients gave written informed consent and
the Ethical Committee of the University Hospital of Palermo approved the protocol of this study
(approval number: RODA-12254).
Diagnosis of MetS was made considering the presence of at least three criteria among those
provided by the modified US National Cholesterol Education Program Adult Treatment Panel III [19],
as follows: (a) waist circumference >88 cm; (b) triglycerides >8.3 mmol/L or on drug treatment for
elevated triglycerides; (c) high-density lipoprotein cholesterol (HDL-C) <2.8 mmol/L or on drug
treatment for reduced HDL-C; (d) type-2 DM, according to current guidelines [20]; (e) blood pressure
>130/90 mm Hg or on anti-hypertensive therapy. Criteria for menopause included: absence of
menstrual period in the preceding year, follicle-stimulating hormone level >50 IU/L, and 17β-estradiol
serum level ≤100 pmol/L (≤27 pg/mL) [2,3].
Family history, physical examination, measurement of body surface area (BSA, m2), waist
circumference (cm) and body mass index (BMI, kg/m2), routine laboratory sampling (fasting glucose,
total cholesterol, HDL-C, low-density lipoprotein cholesterol (LDL-C), triglyceride levels), fasting
serum insulin, and the insulin resistance index by the homeostasis model assessment for insulin
resistance (HOMA-IR) were carried out at baseline, 6 months, and 12 months of therapy. Visfatin,
adiponectin, and homocysteine (HCY) serum levels were also evaluated, as previously described [16].
Patients with a previous or current cardiovascular event, renal or hepatic failure, coagulopathy,
cancer, use of sex hormones or estrogen receptor modulators, steroids, long term treatment with
non-steroidal anti-inflammatory drugs, alcohol abuse, or those who smoked more than two cigarettes
per day were excluded from the study.
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Hypoglycaemic and/or anti-hypertensive drugs were continued during the study period, if
required. Fasting glucose target <8.3 mmol/L and blood pressure≤135/85 mm Hg were recommended
to be achieved in all study participants.
Left ventricular (left ventricle, LV) systolic function was evaluated as the primary endpoint
to analyze the effect of genistein on cardiac function. In particular, LV systolic function and left
atrial (left atrium, LA) morphofunctional indices were investigated according to high-resolution
strain-echocardiography imaging measurements.
2.2. Randomization
Patients from the original trial were assigned by using a computer–generated double–blind
randomization sequence to receive genistein (genistein group) or placebo (control group) twice a day.
Both tablets were supplied by Mastelli srl (Sanremo, Italy). The genistein daily dose was 54 mg and
tablets were identical to the placebo in appearance and taste. Genistein serum levels were measured
both at baseline and the final visit, as previously described [16,21]. Only the first 11 patients of each
group underwent ultrasound studies, due to a budget reduction from the original proposal (Figure 1).
Patients were enrolled according to the computer–generated double–blind randomization sequence,
using the first randomization numbers for each group and maintaining the blinding of researchers
directly involved in the study. Genistein and placebo were given for 12 months.
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Figure 1. CONSORT diagram (Consolidated Standards of Reporting Trials diagram). The first 11 patients
of each arm underwent ultrasound study.
Sample size was calculated in the parent study to provide 80% power to detect an expected
absolute between-group difference in HOMA-IR of 20% after one year of treatment, assuming a
two-tailed level of 0.05 as significant [16].
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2.3. Diet and Exercise
Patients were all recommended to follow a Mediterranean-style dietary regimen (25–30% fat, less
than 10% saturated fatty acids, 55–60% carbohydrates, and 15% protein), but further intake of soy
products or supplements was discouraged.
Regular exercise, such as walking or biking for 80 to 100 min per week, was also suggested to
participants and was recorded weekly for each patient. Dietary and treatment adherence was recorded
at each visit.
2.4. Electrocardiogram and Echocardiogram
After performing a conventional 12-lead electrocardiogram (ECG), ultrasound study was carried
out with a commercially available station (Esaote Mylab 30, Florence, Italy), equipped with an
M–mode, two–dimensional color–Doppler and strain-feature analysis. Imaging was achieved by
the conventional five trans-thoracic views (parasternal long-axis and short-axis, apical 2, 4, and
5 chambers). Quantitative findings were measured as the mean value of three consecutive beats.
Simultaneous ECG monitoring was carried out in each patient. Left ventricular diameters, wall
thickness, mass, systolic and diastolic volumes, ejection fraction (Simpson’s rule biplane method), LA
area and fractional area change [(systolic area minus diastolic area)/systolic area %], as well as LA and
LV longitudinal shortening, were calculated according to recommendations of both the American and
European Societies of Echocardiography [22]. Cardiac chamber volumes and mass were indexed to
body surface area.
Left ventricular systolic function strongly related to ejection fraction. Moreover, LV shape, LV
strain analysis, mitral annulus posterior systolic excursion (MAPSE), and longitudinal function (tissue
S’ velocity) were also evaluated.
We also investigated LV diastolic function by PW-Doppler, sampling the mitral inflow early and
late diastolic velocities (E–wave and A–wave, respectively, and E/A ratio) and tissue–Doppler velocity
both at basal septum level and lateral mitral annulus (E’ velocity, A’ velocity and E/E’ ratio).
A dedicated strain software package (X–Strain TM by Esaote, Florence, Italy) was used for both
LA and LV longitudinal strain [23]. Good quality imaging with an adequate frame rate (50–70 frames
per second) was needed for this purpose. Data were digitally stored and analyzed by a Fourier
equation that warrants heart motion periodicity–based accuracy. Strain curves were generated by
a feature–tracking mode (Figure 2). Strain measurements were generated by processing the region
of interest (several endocardial points from either parasternal short axis or apical 4-chamber view).
Left ventricular longitudinal and circumferential strains are negative, whereas radial strain and peak
atrial longitudinal strain (PALS) are positive values.
2.5. Statistical Analysis
Descriptive statistical analyses were performed to evaluate basal demographic and clinical
characteristics. All results were expressed as medians with interquartile range (IQ) for continuous
variables, and absolute and percentage frequencies for categorical variables.
All variables were evaluated at basal time and after 12 months of treatment, and percentage
changes from baseline were evaluated at the end of the treatment in both genistein and placebo patients
to determine the differences between groups.
The Kolmogorov-Smirnov test for normality was performed to evaluate normal distribution.
Since some of the numerical variables were not normally distributed and the low sample number did
not guarantee valid asymptotic results, a non-parametric approach was used.
The U Mann–Whitney test for independent values was applied to compare characteristics of the
randomized subjects, according to treatment group. In addition, differences within group for paired
measurements were tested by the Wilcoxon signed-rank test analysis.
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Statistical analyses were performed using Statistical Package for Social Science (SPSS Statistics 17.0,
Chicago, IL, USA) software for Windows package. p < 0.05 was considered statistically significant.
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3.2. Clinical and Laboratory Results at Follow-Up
All patients completed the study. Genistein levels increased from 15 nmol/L (95%CI 7.3–22.6) at
baseline to 780 nmol/L (95%CI 741.7–818.3) at 12 months in treated subjects. BMI and waist values
were similar at the end of follow-up in both groups. Resting blood pressure was on target in the
majority of patients (90%) and no differences from basal to the end of follow-up or between groups
were observed. Fasting glucose and insulin levels were simi ar at the beginning d at the end of
follow-up in both groups. After 12 months of treatment, HOMA-IR (p = 0.007), visfatin (p = 0.016),
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and homocysteine (p = 0.034) significantly decreased in the genistein group compared to the controls.
Conversely, serum adiponectin increased in the genistein, but not significantly, compared to the control
group at the end of the treatment (Table 2). Changes in total cholesterol, LDL cholesterol, HDL
cholesterol, and triglycerides at the end of the treatment were similar between groups.
Table 1. Clinical, laboratory, and morphofunctional values measured at baseline and after 12 months,
stratified by treatment groups.
Parameters
Genistein Controls
Basal Median
(IQ)
12 Month
Median (IQ)
# p
Value
Basal Median
(IQ)
12 Month
Median (IQ)
# p
Value
Body mass index (kg/m2) 30.3 (5.0) 31.5 (7.0) 0.167 30.4 (11.2) 29.9 (10.8) 0.593
Waist circumference (cm) 105.0 (16.0) 104.0 (25.0) 0.798 99.0 (19.0) 98.0 (17.0) 0.438
Systolic blood pressure (mm Hg) 130.0 (38.0) 120.0 (40.0) 0.075 130.0 (30.0) 130.0 (20.0) 0.320
Diastolic blood pressure (mm Hg) 80.0 (15.0) 70.0 (30.0) 0.085 80.0 (10.0) 80.0 (0.0) 0.496
Fasting glucose (mmol/L) 7.1 (2.7) 7.0 (0.9) 0.099 7.8 (2.2) 6.5 (4.3) 0.959
Total cholesterol (mmol/L) 4.9 (1.4) 4.2 (0.7) 0.003 4.9 (1.1) 4.4 (1.1) 0.051
LDL-cholesterol (mmol/L) 2.9 (1.1) 1.6 (0.8) 0.009 2.8 (1.3) 2.5 (0.6) 0.120
HDL-cholesterol (mmol/L) 1.3 (0.7) 1.5 (0.6) 0.093 1.3 (0.4) 1.4 (0.6) 0.798
Triglycerides (mmol/L) 1.5 (0.9) 1.2 (0.8) 0.008 1.4 (0.8) 1.2 (0.7) 0.075
Insulin levels (nUI/L) 9.7 (7.8) 8.5 (5.3) 0.050 12.2 (12.3) 13.4 (17.9) 0.477
HOMA-IR 3.4 (1.5) 3.0 (1.7) 0.010 3.7 (4.8) 4.7 (5.2) 0.110
Visfatin (ng/mL) 3.1 (2.0) 1.3 (0.7) 0.016 2.1 (2.2) 2.4 (1.3) 0.477
Adiponectin (µg/mL) 6.2 (1.1) 8.0 (5.9) 0.003 5.3 (2.6) 6.2 (2.6) 0.021
Homocysteine (µmol/L) 13.3 (15.3) 10.0 (2.2) 0.003 17.5 (10.8) 14.2 (7.7) 0.091
Left Ventricle
End-diastolic diameter (mm) 47.4 (9.2) 46.2 (8.2) 0.929 45.8 (7.7) 44.2 (5.1) 0.859
BSA-index mass (g/m2) 82.9 (33.7) 73.0 (27.8) 0.657 78.6 (15.3) 84.7 (19.9) 1.000
Height-indexed mass (g/m2.7) 38.0 (27.7) 44.6 (16.9) 0.328 41.1 (7.9) 39.2 (11.6) 0.859
End-diastolic volume (mL) 67.0 (14.9) 65.0 (26.0) 0.533 72.0 (23.0) 70.0 (28.0) 0.894
BSA-index end-diastolic vol. (mL/m2) 40.3 (13.9) 37.9 (10.5) 0.328 37.2 (10.9) 39.2 (15.1) 0.790
End-diastolic shape 0.6 (0.09) 0.6 (0.1) 0.241 0.6 (0.08) 0.6 (0.1) 0.859
Ejection fraction 0.6 (0.04) 0.7 (0.05) 0.009 0.7 (0.11) 0.7 (0.10) 0.790
MAPSE (mm) 15.8 (4.1) 16.5 (1.3) 0.182 16.3 (4.8) 16.0 (4.9) 0.790
TDV Septal S’-wave (cm/s) 10.0 (3.0) 10.0 (2.0) 0.764 8.0 (4.0) 8.0 (3.0) 0.258
TDV Lateral S’-wave (cm/s) 10.0 (1.0) 12.0 (2.0) 0.022 10.0 (2.0) 11.0 (3.0) 0.305
Left Ventricular Diastolic Indices
Mitral E/A velocity ratio 1.0 (0.23) 0.8 (0.33) 0.449 0.8 (0.44) 0.9 (0.28) 0.965
Mitral E-wave DT (ms) 204.0 (16.0) 216.0 (13.0) 0.075 223.0 (24.0) 242.0 (27.0) 0.059
E/E’ velocity ratio 6.8 (1.0) 7.5 (2.6) 0.533 7.2 (3.5) 7.8 (3.3) 0.859
Left Ventricular Global Strain
Measurements
Radial Strain (%) 32.0 (10.9) 30.0 (15.0) 0.789 36.0 (9.5) 27.9 (12.3) 0.110
Circumferential Strain (%) −21.0 (7.7) −22.5 (4.9) 1.000 −23.5 (9.2) −25.3 (5.0) 0.594
Longitudinal Strain (%) −17.5 (1.5) −17.3 (1.6) 0.328 −15.8 (4.7) −18.8 (4.9) 0.213
Left Atrium
BSA-indexed ES volume (mL/m2) 29.5 (4.2) 22.6 (11.0) 0.041 32.3 (10.2) 27.5 (7.2) 0.248
Fractional area change (%) 37.0 (6.0) 41.0 (6.0) 0.035 35.0 (2.0) 35.0 (5.0) 0.510
PALS (%) 25.5 (5.8) 31.0 (8.5) 0.021 23.6 (10.2) 24.0 (6.5) 0.929
Values are expressed as medians with interquartile range (IQ); BSA, body surface area; DT, deceleration time;
E/A, early/late diastolic velocity through the mitral inflow; E/E’ velocity ratio, ratio between mitral E velocity
and tissue E velocity; ES, end-systolic; HDL high-density lipoprotein; HOMA-IR, homeostasis model assessment
for insulin resistance; LDL, low-density lipoprotein; MAPSE, mitral annular posterior systolic excursion; PALS,
peak atrial longitudinal strain; S’, tissue systolic velocity; TDV, tissue Doppler velocity; # p-values were calculated
using the Wilcoxon rank test for each group, from baseline to the end of the treatment (12 months) as well as
within-group comparisons.
3.3. Cardiac Morphofunctional Indices
Adequate ultrasound imaging was attained from each patient. Changes in cardiac morphology
and function are described in Tables 1 and 2. Both LV ejection fraction (p = 0.040) and LA fractional
area change (p = 0.034) significantly increased in the genistein patients compared the to controls during
the treatment.
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Additionally, LV ejection fraction (p = 0.009), tissue systolic wave velocity at lateral mitral annulus
(p = 0.022), LA volume (p = 0.041), LA fractional area change (p = 0.035), and PALS (p = 0.021) also
significantly improved in genistein-treated patients compared to basal, whereas no differences were
shown in the control group. Advanced echo-strain analysis showed no relevant changes in LV radial,
circumferential, and longitudinal global deformation (Table 2). No advanced LV diastolic dysfunction
was observed. Grade 1–2 diastolic dysfunction was present at enrollment in two genistein patients and
one control. However, at the end of follow-up, just one patient in the genistein group and four in the
placebo group showed diastolic anomalies.
Table 2. Variations of clinical, laboratory values, and morphofunctional findings at Doppler echocardiography
after 12 months of treatment: between groups comparison.
Parameters
Percentage Changes from Baseline after 12 Months Treatment
Genistein Median (IQ) Controls Median (IQ) # p Value
Body mass index (kg/m2) 1.6 (5.7) 0.9 (4.5) 0.171
Waist circumference (cm) 0.0 (4.9) 0.0 (4.4) 0.898
Systolic blood pressure (mm Hg) 0.0 (11.8) 0.0 (12.2) 0.076
Diastolic blood pressure (mm Hg) −8.3 (12.5) 0.0 (6.7) 0.057
Fasting glucose (mmol/L) −7.1 (23.5) −0.9 (18.3) 0.332
Total cholesterol (mmol/L) −12.4 (14.9) −15.5 (23.3) 0.748
LDL-cholesterol (mmol/L) −18.1 (45.1) −16.8 (43.2) 0.270
HDL-cholesterol (mmol/L) 16.3 (27.6) −2.1 (15.6) 0.243
Triglycerides (mmol/L) −12.5 (13.8) −21.5 (56.6) 0.898
Insulin levels (nUI/L) −21.5 (27.9) 1.7 (81.0) 0.193
HOMA-IR −19.7 (39.0) 18.0 (71.2) 0.007
Visfatin (ng/mL) −50.9 (73.2) −7.0 (32.2) 0.016
Adiponectin (µg/mL) 29.4 (62.8) 12.6 (38.6) 0.088
Homocysteine (µmol/L) −24.3 (34.4) −8.1 (50.1) 0.034
Left Ventricle
End-diastolic diameter (mm) 3.2 (14.7) 0.2 (26.5) 0.949
BSA-index mass (g/m2) 2.9 (30.4) 10.5 (41.6) 0.748
Height-indexed mass (g/m2.7) 16.3 (22.2) −5.4 (45.1) 0.519
End-diastolic volume (mL) −1.3 (45.5) −7.8 (67.8) 0.898
BSA-index end-diastolic vol. (mL/m2) −0.4 (49.1) 7.0 (48.5) 1.000
End-diastolic shape 3.2 (5.8) −1.6 (7.6) 0.606
Ejection fraction 20.3 (12.5) −1.7 (24.8) 0.040
MAPSE (mm) 4.4 (38.0) 0.6 (26.4) 0.606
TDV Septal S’-wave (cm/s) 0.0 (26.5) −12.5 (48.1) 0.332
TDV Lateral S’-wave (cm/s) 10.0 (9.1) 9.1 (31.3) 0.606
Left Ventricular Diastolic Indices
Mitral E/A velocity ratio −9.8 (34.8) 6.0 (56.8) 0.652
Mitral E-wave DT (ms) 10.0 (12.4) 6.0 (11.9) 0.748
E/E’ velocity ratio 6.4 (72.6) 3.9 (49.9) 0.748
Left Ventricular Global Strain
Measurements
Radial Strain (%) 12.6 (44.3) −13.4 (35.1) 0.133
Circumferential Strain (%) 0.9 (30.9) 3.7 (38.9) 0.797
Longitudinal Strain (%) −2.8 (11.3) 4.3 (24.9) 0.243
Left Atrium
BSA-indexed ES volume (mL/m2) −22.6 (47.7) −20.8 (61.1) 0.151
Fractional area change (%) 11.1 (22.6) 2.8 (9.5) 0.034
PALS (%) 13.3 (25.4) −11.2 (51.3) 0.270
Values are expressed as medians with interquartile range (IQ); BSA, body surface area; DT, deceleration time;
E/A, early/late diastolic velocity through the mitral inflow; E/E’ velocity ratio, ratio between mitral E velocity
and tissue E velocity; ES, end-systolic; HDL high-density lipoprotein; HOMA-IR, homeostasis model assessment
for insulin resistance; LDL, low-density lipoprotein; MAPSE, mitral annular posterior systolic excursion; PALS,
peak atrial longitudinal strain; S’, tissue systolic velocity; TDV, tissue Doppler velocity; # p-values were calculated
using the Wilcoxon rank test for each group, from baseline to the end of the treatment (12 months) as well as
within-group comparisons.
3.4. Adverse Events and Side-Effects
No clinically relevant side effects, flushing, or palpitations were reported. Nobody experienced
serious arrhythmias or cardiac symptoms.
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4. Discussion
Recent findings indicate that approximately 25% of the USA population shows traits of MetS,
and the constellation of symptoms becomes of clinical concern particularly in postmenopausal patients
with DM and hyperlipemia, whose CV risk is higher than that in the general population. Moreover,
low adherence to treatment with lipid-lowering drugs is particularly high in female patients, strongly
influenced by reimbursement criteria revision, and educational programs in primary care result in
challenging efficacy in reaching the clinical targets. [8,9,24,25]. As a consequence, the increasing
prevalence of MetS over the last decade hinders the efforts of physicians to improve the CV risk profile
through better glycaemic homeostasis [1,2,6,26].
Our group has previously recognized an improvement in the HOMA-IR and several markers of
CV risk of MetS postmenopausal patients treated with genistein [14–16]. Furthermore, the present
findings suggest an interesting impact of genistein treatment on cardiac function in this clinical
setting [12].
Using the strain deformation analysis, the most advanced technique to discover early and
subclinical LV impairment at the present time [23], our results suggest that one year of treatment with
genistein at the dose of 54 mg/day did not worsen LV chamber size or function. On the contrary,
genistein treatment improved LV ejection fraction. Such a gain in LV systolic function cannot be
exclusively attributed to a direct genistein effect on myocardium, but could rather depend on several
factors, including the improvement in adipokine serum levels. In addition, the lack of improvement in
the control group emphasizes the efficacy of the treatment with genistein. Similarly, the improvement
in the LA size and function has been limited to the genistein group. These patients showed a decrease
in LA systolic volume index together with a raise in fractional area change and PALS, without changes
in systo-diastolic blood pressure. This finding is particularly interesting since patients with DM and
hypertension, or MetS, have an increased risk of atrial fibrillation and heart failure [27–29].
Therefore, the present study suggests that genistein could also reduce the LA afterload and
potential dysfunction. In fact, hypertensive, diabetic, and overweight patients have an increased risk of
atrial dysfunction. Significant changes in LA volume and longitudinal deformation might contribute
to the reduction of LA dilatation, fibrosis, and the occurrence of atrial fibrillation, regardless of the
loading conditions at the time of examination [27,28].
The cardioprotective effects of genistein could be partially justified by the improvement in the
adipokine profile. Adiponectin increased significantly over the 12 months in both groups and the
change was not significantly different between groups. Adiponectin promotes insulin-sensitizing
effects and peripheral glucose use, as previously reported [16]. Low circulating levels of adiponectin
were found in obese patients with type-2 DM, as well as in postmenopausal MetS women [30–33].
Adiponectin is a modulator of vascular remodeling, and low serum adiponectin levels are predictors of
atherosclerosis and myocardial infarction, and are associated with higher incidence of cardiovascular
events [34]. These effects are probably related to the anti-inflammatory action of adiponectin, in fact, it
reduces the production of inflammatory cytokines and adhesion molecules in endothelial cells [35].
On the contrary, the pro-inflammatory visfatin was reduced by genistein after one year of
treatment. Visfatin increase in type-2 DM patients was related to heart failure and acute coronary
syndromes [36–39]; visfatin appears to mediate vascular endothelial inflammation by inducing the
expression of adhesion molecules (VCAM-1 and ICAM-1) and pro-inflammatory cytokines such as
IL-1β, IL-6, and TNF-α [40]. These effects on adipokines might explain the observed protective effect on
myocardium. Genistein, by reducing HOMA-IR, may also decrease glucose–mediated cardiotoxicity,
lowering glycated proteins and reactive oxygen species, which are involved in the pathogenesis of
interstitial fibrosis in diabetic cardiomyopathy [41,42].
Among the pro-inflammatory factors, homocysteine, which has been suggested as an independent
risk factor for endothelial dysfunction and atherosclerosis [43], was also reduced by genistein.
Since homocysteine could indirectly impact cardiac function in women with MetS, its reduction in
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genistein-treated patients confirms our previous data obtained in healthy postmenopausal subjects [16]
regarding the possible cardioprotective role of this isoflavone.
Despite the intriguing present results, some limitations of the study should be taken into account.
Our results were obtained from a population without signs of cardiac dysfunction and all women were
of Caucasian origin, thus we do not know if the same effects could be reproduced in different ethnic
groups. The small sample size is a limitation of the present study and no definitive conclusions can be
drawn from our proof of concept study. However, this study was able to demonstrate, for the first
time, that genistein significantly improved cardiovascular function in postmenopausal women with
metabolic syndrome. Accordingly, using this preliminary information, a future larger study expressly
designed to evaluate the effect of genistein on cardiac function is encouraged.
In conclusion, our preliminary data suggest that a daily supplementation with 54 mg of pure
genistein improves both LA remodeling and LV function in postmenopausal women with MetS.
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